Fujifilm to accelerate the manufacturing of Avigan to treat COVID-19
By Akshay Kedari  Date: 2020-04-16

Fujifilm to accelerate the manufacturing of Avigan to treat COVID-19

Fujifilm, a renowned Japanese pharmaceutical company, has reportedly announced plans to boost the production of Avigan, an antiviral drug said to be a possible therapy for coronavirus. Avigan is primarily used to treat Influenza.

The company is aiming to provide this drug in large quantities in order to meet the nationwide growing need for antiviral drugs. The company hopes to produce hundreds of thousands of Avigan doses during the coming months.

The drug maker is currently increasing its production capacity in its Toyoma facility to accelerate the production rate. Since the company is planning large-scale production for Avigan, it has created strategic collaborations with international and domestic firms to provide the raw material for manufacturing Avigan and has also added capacity at its Mako Pure Chemical Co. unit to manufacture active pharmaceutical ingredients of the drug.

Since Fujifilm will now have its massive production in place, it is expecting to produce 100,000 Avigan treatments courses ready for use by July. This number of 3.5 times Avigan’s supply in March and the company has further plans to manufacture 300,000 regimens in place by September.

Japanese drug maker, last month, stated its intentions to accelerate the production of Avigan, after the news made a global impact. However, the company also made some clarifications about its use. The company particularly specified that the Influenza treatment drug has never been distributed in any market and that it is not available in any pharmacies and hospitals across Japan as well as overseas.

Avigan is an antiviral drug developed by the Toyama Chemical unit of Fujifilm and it received approval for sale back in 2014 to treat influenza. However, it was told that this drug can only be used when all other treatments turn out to be ineffective against a re-emerging or novel influenza virus.

While talking about this drug, Shinzo Abe, the Prime Minister of Japan stated that the government would soon initiate tests of Avigan in coronavirus patients in collaboration with other nations and simultaneously accelerate the production while aiming a faster approval for the drug.

Source credit: https://www.fiercepharma.com/manufacturing/fujifilm-speeds-production-potential-covid-19-therapy-avigan

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...

RADCOM introduces automated assurance solution for 5G technology
RADCOM introduces automated assurance solution for 5G technology
By Akshay Kedari

5G technology has been in the headlines for quite a while. Next-generation technology has the potential to transform almost every sector across the world. However, as 5G becomes reality, it has become imperative for service providers to prevent degra...

Sprout to expand wellness solutions lineup by acquiring Vivametrica
Sprout to expand wellness solutions lineup by acquiring Vivametrica
By Akshay Kedari

Sprout, a Canadian company that focuses on delivering innovative solutions for workplace wellbeing, has recently announced the acquisition of predictive health data analytics firm, Vivametrica. According to reliable sources, Sprout plans to enhance t...

Uber halts decision to shift APAC headquarters from Singapore
Uber halts decision to shift APAC headquarters from Singapore
By Akshay Kedari

Uber Technologies Inc., the American ride-hailing giant, has reportedly halted the company’s decision to relocate its Asia Pacific headquarters from Singapore to Hong Kong until December 2022. Sources cite that the company’s decision was...

PCI Pharma extends global clinical supply-chain services in Europe
PCI Pharma extends global clinical supply-chain services in Europe
By Akshay Kedari

U.S. based biopharmaceutical and pharma outsourcing services company, PCI Pharma services has reportedly announced that it reached a noteworthy milestone through the development of COE (Clinical Center of Excellence) in Berlin. According to credible...